• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • John H Sampson, Amy B. Heimberger, +13 authors Darell D. Bigner
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2010 (First Publication: 1 November 2010)
  • PURPOSE Immunologic targeting of tumor-specific gene mutations may allow precise eradication of neoplastic cells without toxicity. Epidermal growth factor receptor variant III (EGFRvIII) is aExpand
  • Jennifer A. Quinn, Sara Jiang, +11 authors Henry S Friedman
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2009 (First Publication: 10 March 2009)
  • PURPOSE This phase II trial was designed to define the role of O(6)-benzylguanine (O(6)-BG) in restoring temozolomide sensitivity in patients with recurrent or progressive, temozolomide-resistantExpand
  • John H Sampson, Kenneth D. Aldape, +15 authors Amy B. Heimberger
  • Medicine
  • Neuro-oncology
  • 2011 (First Publication: 1 March 2011)
  • Epidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation widely expressed in glioblastoma multiforme (GBM) and other neoplasms, but absent from normal tissues.Expand
  • Whitney B. Pope, Xin Joe Qiao, +22 authors Timothy F. Cloughesy
  • Medicine
  • Journal of Neuro-Oncology
  • 2012 (First Publication: 18 March 2012)
  • We have tested the predictive value of apparent diffusion coefficient (ADC) histogram analysis in stratifying progression-free survival (PFS) and overall survival (OS) in bevacizumab-treated patientsExpand
  • Jennifer A. Quinn, Annick Desjardins, +20 authors Henry S Friedman
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2000 (First Publication: 20 October 2000)
  • PURPOSE We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O6-BG effective in producingExpand